Systemic Lupus Erythematosus

DNA Brain Childhood Disability Communication Adolescent Classification Diagnosis Autoimmunity Dendritic cells Complement Age Cytokines Atherosclerosis Compliance Adverse effects Chemokines Apoptosis Antiphospholipid syndrome Antibodies Central Nervous System Complications Autoantibodies Autophagy DNA Methylation Adaptive Immunity Assessment Drug Repositioning animal model Breast cancer Autoimmune disease Chronic kidney disease Deep venous thrombosis Cardiovascular B Cell Receptor Complement system Biomarkers Chromatin remodeling Cervical Cancer Adherence CRP Adjuvant Damage CAPS Antiphospholipid antibodies Biologics Biomarker Diffuse alveolar hemorrhage Calcineurin Drug repurposing Azathioprine Drug metabolism Autoantibody Causes of death Anti-sm Clinical manifestations Cyclophosphamide acute lupus pneumonitis anti-CD28 anti-histone Antinuclear antibodies anti-DNA Antibodies antineutrophil cytoplasmic antibody ASIA-autoimmune/autoinflammatory syndrome induced by adjuvant Antimalarial anti-cardiolipin antibodies Anti-DNA Antiinflammatory anti-prothrombin antibodies BILAG Belimumab brain-reactive antibodies calcineurin inhibitors ANA negative causal variant anti-phospholipid antibodies clarification criteria anti-snRNP Classical pathway congenic constitutional symptoms cancer incidence complement assays creatinine phosphokinase Corynebacterium amycolatum classification criteria disease damage cutaneous lupus erythematosus complement deficiency C3 and C4 DNA hydroxymethylation Disease activity end organ resistance to damage co-stimulator cyclosporine A cutaneous cutaneous lupus DNase1L3 end-organs